At Nemosia, we aim to raise public awareness of neurological disorders and promote a culture where it is seen as normal and safe to do regular brain check-ups even if there are no visible symptoms.
We are developing radiotracers for early diagnostic of neurodegenerative diseases such as multiple sclerosis and Alzheimer's disease.
This diagnosis is performed using PET imaging to visualize receptors inside the brain.
We see Nemosia as the missing piece to support drug development, therapy monitoring patient recruitment and early detection.
The Venture Leaders Biotech dive into the Boston ecosystem (venturelab.swiss)
Sino-Swiss Pitchinar: Selected Swiss biotech startups pitch to Chinese investors and enterprises (venturelab.swiss)
Meet Nemosia co-founder Awa Diagne and discover how they provide the missing piece in the fight against neurodegeneration (venturelab.swiss)
The Venture Leaders Biotech 2021 kick off their international roadshow at the Swiss Biotech Day (venturelab.swiss)
Nemosia wins CHF 150,000 to advance the early detection of neurological degeneration (venturekick.ch)
Venture Leaders Biotech 2021: 10 new Swiss National Startup Team members to showcase Swiss biotech innovation on the global stage (venturelab.swiss)